Fundz
Real-time · AI · Cross-signal

InflaRx N.V just moved. Here's exactly what to do next.

Who to reach, what to say, and why now — on InflaRx N.V, plus every launch, funding round, and exec hire that follows. Verified, ICP-ranked contacts on demand (email + mobile).

Used by professionals at BlackRock, Oracle, Kleiner Perkins, HubSpot, and other leading firms — built on 10 years of proprietary signal data.

Choose your planRequest a demo
▶
Watch the 2-minute tour · with sound

InflaRx N.V. Announces Positive CHMP Opinion for GOHIBIC® (Vilobelimab) for Treating SARS-CoV-2-Induced ARDS.

Nov 15, 2024•over 1 year ago
JenaBiotechnology Research

Product Description

InflaRx N.V. has announced that the European Medicines Agency's CHMP has recommended marketing authorization for their anti-inflammatory therapeutic, GOHIBIC (vilobelimab), for treating adult patients with SARS-CoV-2-induced acute respiratory distress syndrome.

Company Information

Company

InflaRx N.V

Location

Jena, Germany

About

InflaRx (Nasdaq: IFRX) is a clinical-stage biopharmaceutical company focused on applying its proprietary anti-C5a technology to discover and develop first-in-class, potent and specific inhibitors of C5a. Complement C5a is a powerful inflammatory mediator involved in the progression of a wide variety of autoimmune and other inflammatory diseases. InflaRx was founded in 2007 and the group has offices and subsidiaries in Jena and Munich, Germany, as well as Ann Arbor, MI USA.

Predictive Intelligence
Strategic

ML-powered predictions for InflaRx N.V's next move

Learn about Strategic plan

Product Launch Insights

Based on market data
Market expansion signals
New product launches often coincide with market expansion initiatives

Related People

Suggested for you

Choose your plan to view verified contacts